Impact of comorbidities in interstitial pneumonia with autoimmune features (IPAF)

P. Mari (Rome, Italy), S. Kay (Ann Arbor, United States of America), E. Belloli (Ann Arbor, United States of America), M. Salisbury (Ann Arbor, United States of America), J. Sheth (Ann Arbor, United States of America), C. Holtze (Ann Arbor, United States of America), B. Wang (Ann Arbor, United States of America), J. Myers (Ann Arbor, United States of America), K. Konopka (Ann Arbor, United States of America), A. Lagstein (Ann Arbor, United States of America), E. Kazerooni (Ann Arbor, United States of America), A. Chughtai (Ann Arbor, United States of America), D. Vummidi (Ann Arbor, United States of America), V. Nagaraja (Ann Arbor, United States of America), D. Khanna (Ann Arbor, United States of America), K. Flaherty (Ann Arbor, United States of America), L. Richeldi (Rome, Italy), E. White (Ann Arbor, United States of America)

Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Session: Comorbidities of idiopathic pulmonary fibrosis
Session type: Thematic Poster
Number: 1303
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Mari (Rome, Italy), S. Kay (Ann Arbor, United States of America), E. Belloli (Ann Arbor, United States of America), M. Salisbury (Ann Arbor, United States of America), J. Sheth (Ann Arbor, United States of America), C. Holtze (Ann Arbor, United States of America), B. Wang (Ann Arbor, United States of America), J. Myers (Ann Arbor, United States of America), K. Konopka (Ann Arbor, United States of America), A. Lagstein (Ann Arbor, United States of America), E. Kazerooni (Ann Arbor, United States of America), A. Chughtai (Ann Arbor, United States of America), D. Vummidi (Ann Arbor, United States of America), V. Nagaraja (Ann Arbor, United States of America), D. Khanna (Ann Arbor, United States of America), K. Flaherty (Ann Arbor, United States of America), L. Richeldi (Rome, Italy), E. White (Ann Arbor, United States of America). Impact of comorbidities in interstitial pneumonia with autoimmune features (IPAF). 1303

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria
Source: Eur Respir J 2016; 48: 1811-1813
Year: 2016


A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria
Source: Eur Respir J 2016; 48: 1813-1814
Year: 2016


Undifferentiated systemic rheumatic diseases and overlap syndromes: when can we diagnose interstitial pneumonia with autoimmune features (IPAF)?
Source: International Congress 2018 – Respiratory medicine meets rheumatology
Year: 2018


Interstitial pneumonia with autoimmune features (IPAF): a clinical entity?
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019


Characterisation of patients with interstitial pneumonia with autoimmune features
Source: Eur Respir J 2016; 47:1767-1775
Year: 2016



Interstitial pneumonia with autoimmune features (IPAF): the relationship between radiological and clinical features
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020


Interstitial pneumonia with autoimmune features
Source: Guideline 2015
Year: 2015

Interstitial pneumonia with autoimmune features
Source: Eur Respir Monogr 2019; 86: 140-152
Year: 2019


Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF)
Source: Eur Respir J, 51 (4) 1702519; 10.1183/13993003.02519-2017
Year: 2018



Clinical significance of histological UIP pattern in interstitial pneumonia with autoimmune features (IPAF)
Source: International Congress 2017 – Novel and old entities
Year: 2017


Different characteristics and outcomes of acute exacerbation: comparison between interstitial pneumonia with autoimmune features and lone idiopathic interstitial pneumonia.
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018


Clinical features of patients with desquamative interstitial pneumonia: Association with autoimmune disorders
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010


Interstitial pneumonia with autoimmune features: a new classification still on the move
Source: Eur Respir Rev, 27 (148) 180047; 10.1183/16000617.0047-2018
Year: 2018



Clinical spectrum of children with interstitial pneumonia with autoimmune features:a new definition in childhood interstitial lung diseases
Source: Virtual Congress 2021 – Posters in paediatric bronchology
Year: 2021


Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment?
Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease
Year: 2020


Interstitial pneumonitis with autoimmune features (IPAF): a work in progress
Source: Eur Respir J 2016; 47:1622-1624
Year: 2016


Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders?
Source: Eur Respir J 2011; 38: 384-391
Year: 2011



Idiopathic non-specific interstitial pneumonia (NSIP): is it an autoimmune clinical entity?
Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases
Year: 2007


Prevalence and clinical characteristics of unclassifiable idiopathic interstitial pneumonias (IIPs)
Source: International Congress 2017 – Novel and old entities
Year: 2017


Clinical, functional and radiologic progression in Interstitial pneumonia with autoimmune features (IPAF): a prospective cohort-study
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020